IDH2 and central nervous system cancer: Recent studies have shown that IDH mutant glioma cells produced more TEX than IDH wild-type glioma cells and were able to cross the blood-brain barrier to target anatomical sites (bone marrow, spleen) with abundant immune cells for phenotypic/functional regulation of circulating immune cells.